Q-omics provides the consensus-scored CKAP2LP1 profile across patient tissues and cancer cell-line models. CKAP2LP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CKAP2LP1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, CKAP2LP1 RNA expression shows 11,259 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, KIRC, and GBM as cancer lineages where CKAP2LP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CKAP2LP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CKAP2LP1 survival associations across molecular data types. CKAP2LP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CKAP2LP1 RNA expression–survival associations across cancer types. High CKAP2LP1 expression shows unfavorable associations in LUAD, DLBC, THCA and COAD, but favorable associations in ESCA and UCS. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for CKAP2LP1 RNA expression.
This table summarizes CKAP2LP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CKAP2LP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CKAP2LP1 shows lower tumor expression in BRCA and higher tumor expression in KIRC, STAD and KIRP. The KIRC box plot shows higher CKAP2LP1 RNA expression in tumor versus normal tissue (log2 FC = +0.192, t-test p < 0.001).
This table shows molecular features associated with CKAP2LP1 in patient tissues and cancer cell lines. In patient samples, CKAP2LP1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
